Abstract
The human malarial parasite, Plasmodium falciparum, is responsible for one of the most infectious diseases of the world and is quickly gaining resistance to the commonly used antimalarial treatments. New data are continually reinforcing the idea that biological functions associated with the ubiquitin proteasome system (UPS) are not just limited to non-lysomal degradation of proteins but consist of a wide array of regulatory mechanisms such as cell cycle progression, transcriptional regulation, gene expression and trafficking. While there is much effort in understanding the UPS in many eukaryotic organisms, the Plasmodium UPS has been relatively understudied despite its potential as a therapeutic drug target. However, in vitro proteasome inhibitors studies have confirmed the essentiality of the UPS in Plasmodia with limited toxicity to human cell lines. In addition, computational studies have shown that there are a number of ubiquitinating proteins upstream of the proteasome that may serve as parasite-specific drug targets due to their variety and divergences from other eukaryotic species. In this review, we highlight the major findings about Plasmodiums UPS and discuss its possible implications as an effective and specific antimalarial target.
Keywords: Plasmodium falciparum, ubiquitin proteasome system, drug discovery, ubiquitin-ligase, malaria
Infectious Disorders - Drug Targets
Title: Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future
Volume: 10 Issue: 3
Author(s): Duk-Won Doug Chung and Karine G. Le Roch
Affiliation:
Keywords: Plasmodium falciparum, ubiquitin proteasome system, drug discovery, ubiquitin-ligase, malaria
Abstract: The human malarial parasite, Plasmodium falciparum, is responsible for one of the most infectious diseases of the world and is quickly gaining resistance to the commonly used antimalarial treatments. New data are continually reinforcing the idea that biological functions associated with the ubiquitin proteasome system (UPS) are not just limited to non-lysomal degradation of proteins but consist of a wide array of regulatory mechanisms such as cell cycle progression, transcriptional regulation, gene expression and trafficking. While there is much effort in understanding the UPS in many eukaryotic organisms, the Plasmodium UPS has been relatively understudied despite its potential as a therapeutic drug target. However, in vitro proteasome inhibitors studies have confirmed the essentiality of the UPS in Plasmodia with limited toxicity to human cell lines. In addition, computational studies have shown that there are a number of ubiquitinating proteins upstream of the proteasome that may serve as parasite-specific drug targets due to their variety and divergences from other eukaryotic species. In this review, we highlight the major findings about Plasmodiums UPS and discuss its possible implications as an effective and specific antimalarial target.
Export Options
About this article
Cite this article as:
Doug Chung Duk-Won and G. Le Roch Karine, Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future, Infectious Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187152610791163345
DOI https://dx.doi.org/10.2174/187152610791163345 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contrast Media in Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Nuclear Import of the Pre-Integration Complex (PIC): The Achilles Heel of HIV ?
Current Drug Targets NAD Precursors, Mitochondria Targeting Compounds and ADP-Ribosylation Inhibitors in Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design HER-2 Positive Breast Cancer: What Else Beyond Trastuzumab-Based Therapy?
Anti-Cancer Agents in Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Editorial (Thematic Issue: Embryonic Signaling Pathways as Potential Targets for the Treatment of Rhabdomyosarcoma)
Current Drug Targets